154 results on '"Matar, Manar"'
Search Results
2. Recurrence rates following ileo-colic resection in pediatric patients with Crohn’s disease
3. Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha
4. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study
5. Sexual health in adolescents with inflammatory bowel disease – The paediatric gastroenterologists' point of view
6. Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN.
7. Clinical characteristics and outcomes of pediatric patients with autoimmune gastritis.
8. Different infliximab induction dosing regimens do not affect remission rates up to 1 year in children with Crohn's disease.
9. De Novo Crohn's Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch–Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN.
10. Pediatric inflammatory bowel disease and the effect of COVID-19 pandemic on treatment adherence and patients’ behavior
11. Liraglutide effects on glycemic control and weight in patients with type 2 diabetes Mellitus: A real-world, observational study and brief narrative review
12. Two decades of pediatric celiac disease in a tertiary referral center: What has changed?
13. Clinical Features and Outcomes of Paediatric Patients With Isolated Colonic Crohn Disease
14. High anti-TNFα Concentrations Are Not Associated With More Adverse Events in Pediatric Inflammatory Bowel Disease
15. Adherence to the Mediterranean Diet Is Associated with Decreased Fecal Calprotectin Levels in Children with Crohn's Disease in Clinical Remission under Biological Therapy.
16. De Novo Crohn’s Disease in Children With Ulcerative Colitis Undergoing Ileal Pouch–Anal Anastomosis: A Multicenter, Retrospective Study From the Pediatric IBD Porto Group of the ESPGHAN
17. Outcome of Very Early Onset Inflammatory Bowel Disease Associated With Primary Sclerosing Cholangitis: A Multicenter Study From the Pediatric IBD Porto Group of ESPGHAN
18. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohn’s Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
19. Positivity of Stool Pathogen Sampling in Pediatric Inflammatory Bowel Disease Flares and Its Association With Disease Course
20. Comparison of Clinical Outcomes in Pediatric Patients with Ileocolonic Crohn Disease Treated with Infliximab Versus Adalimumab
21. Dual Biologic or Small Molecule Therapy in Refractory Pediatric Inflammatory Bowel Disease (DOUBLE-PIBD): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN.
22. New-onset Blepharitis and Anti-TNF-Alpha Therapy in Patients with Crohn's Disease: A Case Series and Literature Review.
23. Combination Therapy of Adalimumab With an Immunomodulator Is Not More Effective Than Adalimumab Monotherapy in Children With Crohnʼs Disease: A Post Hoc Analysis of the PAILOT Randomized Controlled Trial
24. The Effect of Adalimumab Treatment on Linear Growth in Children With Crohn Disease: A Post-hoc Analysis of the PAILOT Randomized Control Trial
25. Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease
26. Gluten Immunogenic Peptides are not correlated with reported adherence to gluten-free diet in children with celiac disease
27. Trough Concentration Response in Infliximab and Adalimumab Treated Children With Inflammatory Bowel Disease Following Treatment Adjustment: A Pharmacokinetic Model
28. Correlation between the Nancy Histopathology Index and Markers of Disease Activity in Pediatric Ulcerative Colitis
29. Recurrence rates following ileo-colic resection in pediatric patients with Crohn’s disease
30. Safety and Potential Efficacy of Escalating Dose of Ustekinumab in Pediatric Crohn Disease (the Speed-up Study): A Multicenter Study from the Pediatric IBD Porto Group of ESPGHAN
31. Oesophageal eosinophilia in children with coeliac disease
32. 983: OUTCOME OF INDUCTION THERAPY WITH VEDOLIZUMAB IN CHILDREN: RESULTS FROM THE PROSPECTIVE, MULTICENTER, VEDOKIDS STUDY
33. 524: PATHOGENIC RIPK1 MUTATIONS CAUSE INFANTILE-ONSET IBD WITH INFLAMMATORY AND FISTULIZING FEATURES
34. Pediatric inflammatory bowel disease: Fecal calprotectin response to Anti-tumor necrosis factor alpha
35. sj-docx-1-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases
36. sj-docx-2-tag-10.1177_17562848211068659 ��� Supplemental material for Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases
37. CLINICAL FEATURES AND OUTCOMES OF PAEDIATRIC PATIENTS WITH ISOLATED COLONIC CROHN’S DISEASE: A MULTICENTRE STUDY FROM THE PAEDIATRIC IBD PORTO GROUP OF ESPGHAN
38. Risk of consecutive immunogenic failure in switchers of anti-tumor necrosis factor alpha among patients with inflammatory bowel diseases
39. Clinical Features and Outcomes of Paediatric Patients With Isolated Colonic Crohn Disease
40. Intestinal Fatty Acid Binding Protein Levels in Pediatric Celiac Patients in Transition From Active Disease to Clinical and Serological Remission
41. Age-Dependent Trends in the Celiac Disease: A Tertiary Center Experience
42. Positivity of Stool Pathogen Sampling in Pediatric Inflammatory Bowel Disease Flares and Its Association With Disease Course
43. Appraisal of the PIBD-classes Criteria: A Multicentre Validation
44. Therapeutic Drug Monitoring Increases Drug Retention of Anti–Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn’s Disease
45. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn’s Disease Compared With Reactive Monitoring
46. Endoscopic Findings in Children with Isolated Lower Gastrointestinal Bleeding
47. COMPARABLE CLINICAL OUTCOMES IN PEDIATRIC PATIENTS WITH CROHN'S DISEASE TREATED WITH ACCELERATED VS. STANDARD INFLIXIMAB DOSING DURING INDUCTION.
48. Hypergammaglobulinemia is a marker of extraintestinal manifestations in pediatric inflammatory bowel disease
49. The Influence of Excessive Chewing Gum Use on Headache Frequency and Severity Among Adolescents
50. The Nancy Histopathological Index has limited value in predicting clinical outcomes in newly diagnosed pediatric patients with ulcerative colitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.